Table 1.

Studies evaluating the use of necroptosis inhibition for treating neurodegenerative conditions

Condition	Mode of inhibition	Outcome	References
Alzheimer’s disease (AD)	Necrostatin-1	Improved behavior and reduction in AD-induced neuronal death	[51, 104]
		Reduced Aβ and Tau deposition
		Amelioration of cognitive impairment
Amyotrophic lateral sclerosis (ALS)	RIPK1/3 Mutation	Increased neuron viability in ALS-causing optineurin (OPTN)−/− mice	[91, 121]
	Necrostatin-1	Improved neuron survival in ALS astrocyte co-cultures in vitro
Huntington’s disease (HD)	Necrostatin-1	Improved behavior and delayed symptom onset in HD murine model	[122]
Parkinson’s disease	Necrostatin-1	Necroptotic inhibition protected dopaminergic neurons in culture	[123]